The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Oruka Therapeutics Inc shares valued at $1,015,803 were purchased by Venrock Healthcare Capital Par on Feb 14 ’25. At $11.44 per share, Venrock Healthcare Capital Par acquired 88,794 shares. The insider’s holdings grew to 4,148,428 shares worth approximately $49.7 million following the completion of this transaction.
Also, Venrock Healthcare Capital Par purchased 14,950 shares, netting a total of over 173,868 in proceeds. Following the buying of shares at $11.63 each, the insider now holds 4,059,634 shares.
Before that, Venrock Healthcare Capital Par had added 8,971 shares to its account. In a trade valued at $106,396, the 10% Owner bought Oruka Therapeutics Inc shares for $11.86 each. Upon closing the transaction, the insider’s holdings increased to 8,971 shares, worth approximately $48.46 million.
As published in their initiating research note from BTIG Research on May 22, 2025, Oruka Therapeutics Inc [ORKA] has been a Buy and the price target has been revised to $44. Analysts at Wolfe Research started covering the stock with ‘”an Outperform”‘ outlook in a report released in early February. As of October 11, 2024, Stifel has initiated its “Buy” rating for ORKA. Earlier on October 07, 2024, H.C. Wainwright initiated its rating. Their recommendation was “a Buy” for ORKA stock.
Analyzing ORKA Stock Performance
On last trading session,, Oruka Therapeutics Inc [NASDAQ: ORKA] rose 0.08% to $11.98. The stock’s lowest price that day was $11.83, but it reached a high of $12.32 in the same session. During the last five days, there has been a drop of approximately -4.92%. Over the course of the year, Oruka Therapeutics Inc shares have dropped approximately -38.22%. Shares of the company reached a 52-week high of $21.32 on 01/06/25 and a 52-week low of $5.49 on 04/09/25.
Support And Resistance Levels for Oruka Therapeutics Inc (ORKA)
According to the 24-hour chart, there is a support level at 11.75, which, if violated, would cause prices to drop to 11.53. In the upper region, resistance lies at 12.26. The next price resistance is at 12.55. RSI (Relative Strength Index) is 53.99 on the 14-day chart, showing neutral technical sentiment.
Is Oruka Therapeutics Inc subject to short interest?
Stocks of Oruka Therapeutics Inc saw a sharp rise in short interest on 2025-05-30 jumping by 93172.0 shares to 2.76 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 2.66 million shares. A jump of 3.38% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 19.56 of the overall float, the days-to-cover ratio (short ratio) jumped to 19.56.
Which companies own the most shares of Oruka Therapeutics Inc (ORKA)?
In terms of Oruka Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 20 in the next 12 months, up nearly 67.08% from the previous closing price of $11.97. Analysts anticipate Oruka Therapeutics Inc stock to reach 20 by 2025, with the lowest price target being 20. On September 17, 2024, Leerink Partners assigned a price target of “an Outperform” to the stock and initiated coverage with a $44.
